[go: up one dir, main page]

WO2007033135A2 - Procédé de fabrication d'agents hémostatiques et leurs utilisations - Google Patents

Procédé de fabrication d'agents hémostatiques et leurs utilisations Download PDF

Info

Publication number
WO2007033135A2
WO2007033135A2 PCT/US2006/035417 US2006035417W WO2007033135A2 WO 2007033135 A2 WO2007033135 A2 WO 2007033135A2 US 2006035417 W US2006035417 W US 2006035417W WO 2007033135 A2 WO2007033135 A2 WO 2007033135A2
Authority
WO
WIPO (PCT)
Prior art keywords
starch
hemostatic
manganese oxide
molecular sieve
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/035417
Other languages
English (en)
Other versions
WO2007033135A3 (fr
Inventor
Robert E. Moore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IMED SCIENTIFIC Corp
Original Assignee
IMED SCIENTIFIC Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IMED SCIENTIFIC Corp filed Critical IMED SCIENTIFIC Corp
Publication of WO2007033135A2 publication Critical patent/WO2007033135A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007033135A3 publication Critical patent/WO2007033135A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides

Definitions

  • the present disclosure relates generally to the process of manufacturing molecular sieve in paper-like and rubber-like forms, and more particularly, to the process of manufacturing sieve materials for us as hemostatic agents and for other industrial uses.
  • Body fluid loss and conservation of that body fluid arise under a variety of situations.
  • One situation occurs with acute trauma.
  • acute trauma is the result of a serious accident or a battlefield injury.
  • the patient can be in a life- threatening situation from exsanguination, among other things. Stopping blood loss and conserving blood components becomes a priority and failure to do so can result in death.
  • An agent that stops bleeding and fluid loss quickly and efficiently represents a valuable tool for medical professionals and first responders.
  • burns are a common injury that are difficult to treat because of the large area of the body usually involved, pain, the high risk of infection, and the general nature of the healing process.
  • Controlling fluid loss has been approached using various hemostatic agents and application methods. Previous solutions can be grouped into a few general classes; however, many incorporate a common approach, which is to trigger the clotting cascade by concentrating the natural cellular promoters of clot formation.
  • a large group of products addressing fluid loss are hemostatic agents derived from collagen.
  • platelets adhere to collagen and are then activated.
  • Hemostatic products such as University of Arizona's MedStat-FTM, Davol, Inc.'s Avitene ⁇ , Pharmacia and Upjohn's Gelfoam®, and Integra NeuroScience's Helistat® are all based on collagen. These are animal source collagen products and must be treated accordingly to ensure that they are non-pyrogenic and non-immunogenic. Unfortunately, animal based products require expensive collection and processing procedures to minimize immunogenicity and pyrogenicity.
  • Nycomed Austric GmbH's TachoComb® is also a collagen product coated with fibrinogen, thrombin, and aprotinin. These are naturally occurring clotting agents, however, and unfortunately they can be very expensive and not practical for wide spread use. Furthermore, as they are naturally occurring the quality of the product may vary from lot to lot.
  • Another group of hemostatic agents are a variety of molecular sieves. These materials adsorb water and concentrate the cellular material, thus initiating the clotting process.
  • Z-Medica's QuickClotTM a zeolite, is one of these products.
  • Molecular sieves absorb water through the process of hydration. Unfortunately, hydration is an exothermic reaction which can create large amounts of heat. Significant heat caused by hydration can lead to tissue damage causing short and long term side effects.
  • Most of the approaches and products mentioned above are in powder or granular form and are applied by sprinkling or dusting the wound. These application methods make accurate and precise application of the products difficult. Moreover, some of these products are non-biodegradable and must be removed from the body.
  • an application of chemical hemostatic agents is provided that utilizes chemical hemostatic agents in forms that can be accurately applied, quickly initiate clotting action, are easily removed if necessary and do not cause any permanent tissue damage.
  • the method of application utilizes synthesized manganese oxide as an effective chemical hemostat.
  • the manganese oxide is synthesized according to U.S. patents 6,503,476, 6,486,357, 5,702,674, and 5,635,155, which are incorporated by reference in their entirety.
  • Manganese oxide synthesized by the above referenced patents and contemplated by the current disclosure advantageously self-assembles into helices, rings, and strands forming an advantageous porous crystalline structure.
  • the current disclosure also contemplates manganese oxide as an octahedral molecular sieve.
  • the molecular sieve can by synthesized to produce manganese oxide hydrates of various structures, including, but not limited to, pyrolusite, nsutite, romanechite, todorokite, and hollandite. These synthesized forms of manganese oxide offer greater purity and crystallinity and porosity than various naturally occurring minerals.
  • the hydration of manganese oxide of these forms and application thereof creates insignificant heat. Therefore, no considerable thermal tissue damage occurs with application according to the current disclosure.
  • the present disclosure provides, among other things, a method for applying synthesized manganese oxide in a granular form that incorporates easy application and removal of the inorganic product.
  • the structure of the granular material allows for controlled release of medicaments and can be engineered to specific pore size to selectively allow the passage of biomolecules in either direction.
  • the synthesized manganese oxide is attached to or encased in a material including, but not limited to, Teflon®, silk, cotton, rayon, TeflaTM, gauze, paper, or other fabrics that will readily conform to the contours of the body.
  • a material including, but not limited to, Teflon®, silk, cotton, rayon, TeflaTM, gauze, paper, or other fabrics that will readily conform to the contours of the body.
  • the manganese oxide when attached to or encased with materials will effectively adsorb water from flowing body fluid and concentrate the cellular matter to initiate the clotting process. Synthesized manganese oxide in combination with the binding and encasing materials according to the invention is easily applied and removed.
  • the synthesized manganese oxide is incorporated into a paper like material that will readily conform to the contours of the body.
  • the synthesized manganese oxide when incorporated into a paper like material will effectively adsorb water from flowing body fluid and concentrate the cellular matter to initiate the clotting process.
  • Synthesized manganese oxide in combination with the paper like material according to the invention is easily applied and removed.
  • a block polymer is utilized in the method of application. The polymer can be used as a support for the synthesized manganese oxide and or for additional haemostatic agents to increase the overall efficiency of the final product.
  • the block polymer in itself is a hemostatic agent and in a first illustrative embodiment is comprised of alpha hydroxyacids, alcohols, and glycols.
  • These block polymers according to the invention can be engineered for biodegradability and molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • the block polymers may be formed into sheets, strips, foam, sponges, gels, or other various particle forms.
  • the polymer in these forms is biologically absorbable and non-reactive.
  • the product, when formed in large, thin sheets is strong and pliable materials that may be used to protect large area wounds including, but not limited to bums.
  • the large area polymeric sheets allow for the passage of water and air, but are advantageously not bacterial. This embodiment of the current disclosure will minimize fluid loss and reduce the incidence of infection while allowing for easy application to a specific injury site.
  • the block polymers may be in a soft and pliable form.
  • the pliable polymers can be used to form a plug that can be utilized during catheterization procedures to eliminate excessive bleeding from a puncture site. Due to the absorbable and hemostatic nature of the polymer, it can be produced to be used in dental extractions to reduce the incidence of dry socket.
  • a hemostatic ointment is utilized in the method of application.
  • the hemostatic ointment is comprised of silver and calcium compounds incorporated into a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2-hydroxyproply ether.
  • a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2-hydroxyproply ether.
  • This hemostatic ointment according to the invention can be engineered for biodegradability and molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • a hemostatic agent for humans it also has application within veterinary application.
  • a hemostatic dry aerosol is utilized in the method of application.
  • the hemostatic dry aerosol is comprised of silver and calcium compounds incorporated into a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2-hydroxyproply ether.
  • This dry aerosol formulation is incorporated with dry flow agents known in the art to allow for ease of application.
  • This hemostatic dry aerosol according to the invention can be engineered for b molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • a hemostatic agent for humans it also has application within veterinary applications.
  • a hemostatic bandage is utilized in the method of application.
  • the hemostatic bandage is comprised of a natural or polymeric fabric sheet having a layer of silver and calcium compounds incorporated into a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2- hydroxyproply ether.
  • a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2- hydroxyproply ether.
  • This hemostatic bandage according to the invention can be engineered for biodegradability and molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • a hemostatic agent for humans it also has application within the veterinary practice.
  • a physiologically degradable hemostatic bandage is utilized in the method of application.
  • the physiologically degradable hemostatic bandage is comprised of a polymeric sheet encasing hemostatic compounds such as silver and calcium compounds incorporated into a starch based hemostatic agent such as but not limited to amylopectin phosphate, 2- hydroxyproply ether.
  • This physiologically degradable hemostatic bandage according to the invention can be engineered for biodegradability and molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • a polymeric sheet is wrapped around the hemostatic material.
  • a hemostatic agent for humans it also has application within the veterinary practice.
  • a hemostatic agent comprised substantially of synthesized manganese oxide is used as effective chemical hemostat.
  • the manganese oxide is synthesized according to U.S. patents 6,503,476, 6,486,357, 5,702,674, and 5,635,155, which are incorporated by reference in their entirety.
  • Manganese oxide synthesized by the above referenced patents and contemplated by the current disclosure advantageously self-assembles into helices, rings, and strands without any imposed concentration gradient.
  • the assembled physical structure of the synthetic manganese oxide has been advantageously found to have desirable hemostatic properties.
  • the synthesized manganese oxide is dialyzed against a strong Ca solution to increase its calcium content. Without being bound to any particular theory it is thought that the increased calcium content increases the hemostatic properties of the synthesized manganese oxide.
  • molecular sieves can by synthesized to produce manganese oxide hydrates of various structures, including, but not limited to, pyrolusite, nsutite, romanechite, todorokite, and hollandite. These synthesized forms of manganese oxide offer greater purity and crystallinity than various naturally occurring mineral and the crystalline structure with its porous nature offers a hemostatic agent having no exothermic properties upon hydration.
  • the synthesized forms of manganese oxide according to the invention may be directly applied to wound surfaces or held in place by pressure. It is contemplated within the scope of the disclosure that these synthesized forms of manganese oxide may be free flowing or be supported on or in a containment system. For example, the synthesized forms of manganese oxide may be adhered to the surface of a sheet or film which is applied (e.g., contacted, wrapped, adhered, secured, affixed or otherwise place into a position where blood on the wound area will be absorbed or adsorbed by the synthesized forms of manganese oxide) to areas of a wound or surgical incision.
  • the synthesized forms of manganese oxide according to the invention may also be provided interspersed with fibers, filaments or other particles in a self-supporting structure, entangled within the fibrous elements of a net, web, fabric or sheet, embedded in a sheet or film (with the manganese oxide enable in a manner for the adsorption or absorption of blood in contact with the wound), a packet of material, with the manganese oxide free-flowing within the confines of the packet. It is contemplated within the scope of the disclosure that the synthesized manganese oxide may be in various physical crystalline structures as produced by the methods in the patents referenced above.
  • the synthesized forms of manganese oxide may be combined with other hemostatic materials such as, but not limited to, porous particulates as described in U.S. Patent No. 6,060,461 to Drake, the teachings of which are incorporated in its entirety by reference.
  • the manganese oxide according to the invention may also be provided as part of a patch system, with a fibrous network associated with the manganese oxide providing a high level of structural integrity and strength to the applied assembly over the wound or surgical incision, even before clotting has occurred. This would be particularly appropriate where the assembly was being used as a stitch replacement or true wound closure system rather than only promoting clotting. It is contemplated within the scope of the disclosure that the porous particles may easily be associated with or carry additional, but optional, clotting or wound treating materials or ingredients. It is further contemplated that it would be desirable to provide the synthesized manganese oxide with anti-microbials, antifungal agents, topical pain reducing medication, pharmaceutical additives, anti-inflammatants, mixtures thereof and the like.
  • Anti -microbial additives utilized as pharmacological additives within the present disclosure include the biguanides, especially chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampician, bacitracin, neomycin, chloramphenical, miconazole, tolnaftate, quinolones such as oxolinic acid, norfloxacin, nalidix acid, pefloxacin, enoxacin and ciproflox
  • organic compounds derived from plants and herbs having desirable pharmacological properties can be utilized as pharmacological additives. Extracts of plants and herbs have been known to possess anti-microbial activity and their use has been shown to be safe for human and animal consumption. Extracts of such plants, known as phytochemicals, may be utilized for their anti-microbial properties. Some of these extracts, such as grapefruit seed extract, Tea Tree Oil and Myrtle Oil and others can be incorporated into the hemostatic composition and their anti-microbial properties released to the surrounding tissue in an efficacious manner.
  • a block polymer is utilized in the method of application.
  • the block polymer according to the disclosure has hemostatic properties and can be used as a support or substrate for additional hemostatic agents to increase the overall efficiency of the final product.
  • the block polymer is used as a substrate to support the synthesized manganese oxide. It is contemplated within the scope of the invention that the block polymer can be used to support other hemostatic agents known in the art.
  • the block polymer hemostatic agent is comprised of alpha hydroxyacids, alcohols, and glycols.
  • These block polymers according to the invention can be engineered for biodegradability and molecular characteristics beneficial to specific applications, i.e., to allow for various surgical or healing requirements.
  • the block polymer is synthesized according to a synthesis adopted from the literature (Biomaterials Volume 26, Issue 36, December 2005, Pages 7555-7563; Synthesis of degradable poly (1-lactide-co-ethylene glycol) porous tubes by liquid-liquid centrifugal casting for use as nerve guidance channels; Alex Goraltchouka, Thomas Freiera, and Molly S. Shoi tribe,), the contents of which are incorporated by reference in their entirety.
  • the following synthesis is used to create the block polymer according to the invention:
  • hemostatic block polymers materials such as but not limited to, poly (lactic acid), poly(glycolic acid), poly(caprolactone), polyethylene glycol of molecular weights 200 to 6000, hydroxyvalerate, and B-malonic acid can be used.
  • the formation of a hemostatic block polymer film according to the disclosure is done by casting a solution (methylene chloride) on flat glass plates and drying the solution. Sponges and gels are formed in a similar manner except the drying is done under vacuum and usually includes a water soluble salt or other compound. When the product has been dried of the organic solvent, it is washed with water and the salt is dissolved. This leaves pores, channels, and voids that can be used for channeling water away from the wound. In all these cases the flexibility of the final product is dependent upon the polyethylene glycol molecular weight and concentration in the polymer.
  • a hemostatic block polymer is formed of about 45% poly(lactic acid), about 45% poly(glycolic acid) and about 10% polyethylene glycol Mw 6000.
  • This particular block polymer forms a porous film according to the disclosure.
  • This block polymer formed as a film can be used as a substrate for at least one additional clotting agent in or on top of the film. It is contemplated within the scope of the disclosure that at least one additional clotting agent can be pressed into the surface of the film or it can be suspended into the solution and dried within the film. It is further contemplated within the scope of the disclosure that formation of a block polymer film having a porous makeup forming a sponge like material, can have synthesized manganese oxide incorporated in the sponge like material.
  • the block polymers according to the disclosure may be formed into sheets, strips, foam, sponges, or other various particle forms. Desirably, the block polymer in these forms is biologically absorbable and non-reactive. According to the invention the block polymer, when formed in large, thin sheets is strong and pliable that may be used to protect large area wounds including, but not limited to burns.
  • the large area polymeric sheets allow for the passage of water and air, but are advantageously not bacterial.
  • the block polymer according to the invention will minimize fluid loss and reduce the incidence of infection while allowing for easy application to a specific injury site.
  • synthesized manganese oxide according to the disclosure is incorporated in a paper like form by suspending the synthesized manganese oxide with other materials in solution and then drying the material at a controlled temperature. The temperature at which the drying is done determines the ultimate physical characteristics of the finished paper product. Additional materials in this process are any material known in the art that can add strength and increase thickness, such as but not limited to cellulosics or the like.
  • fibers such as wool, cotton, wood pulp, synthetic fabrics, metals and cellulosics or the like can be added to increase strength and performance characteristics of the paper like material.
  • this manganese oxide like paper on substrates known in the art such as gauze, screens, webs, and any sort of support.
  • substrates known in the art such as gauze, screens, webs, and any sort of support.
  • the use of a substrate will give a convenient form, shape and or geometry to the manganese oxide like paper for applications to varying wound or incision sites.
  • the manganese oxide is susceptible to magnetic fields, that forming the paper in the presence of an electromagnetic field will align the manganese fibers to enhance the character of the material for this use and other applications that require fibers in a specific orientation.
  • Example I In an illustrative embodiment according to the disclosure, potassium sulfate, potassium persulfate and manganese sulfate monohydrate are combined in a stoichiometric ratio of 3:3:2 and dissolved in distilled, deionized water (DDW). This mixture is sealed in a Teflon®' stainless steel vessel and heated to about 250 C for about 4 days.
  • This paper like method is partially disclosed in the journal article entitled “Spontaneous Formation of Inorganic Paper-Like Materials” Yuan et al. ( Advanced Materials DOl: 10.1002/adma.200400659) ("Yuan”), the contents of which are incorporated by reference in its entirety.
  • the resulting product is a rigid, solid material that is then suspended in DDW and stirred for 12 to 14 hours producing a slurry.
  • the slurry material is dialyzed against a strong Ca solution to increase its calcium content.
  • the dialyzed slurry is poured onto a glass plate or other appropriate substrate and heated to about 85 C for about 24 hours. After drying the resultant paper like material is removed and ready for use in applications.
  • Example II In a further illustrative embodiment according to the disclosure a process and composition of material that allows the efficient and cost effective production of inorganic sieve materials for use in multiple applications is contemplated.
  • manganese oxide can be compounded with a starch or starch like material to form a rubber-like material that can be extruded through a die to generate uniform particles. It is contemplated within the scope of the invention that molecular sieve other than manganese oxide can be used. It is also contemplated within the scope of the invention that the starch can be from plant sources or the starch can be a synthesized starch like material or the like.
  • the generated uniform particles are then thermally rearranged, as set forth in the synthesis shown in Example I.
  • the thermal rearrangement is achieved by placing the uniform particles in a sealed Teflon®, stainless steel vessel and heated to about 250 C for about 4 days as described in Yuan.
  • the resultant octahedral molecular sieve can be used in various applications.
  • Materials that can be compounded with the molecular sieve to form the rubber-like material include such classes of compounds such as starches, sugars, plasticizers, polyvinyl alcohols, long chain alcohols, mannitol, microcrystalline starch, salts of steric acid, dicalcium phosphate, binding agents or the like. It is contemplated within the scope of the disclosure that it is possible to generate large sheets of molecular sieve material by compounding the molecular sieve with these binding agents at the gel stage of the synthesis. The gel can be extruded or rolled to fit the shape and size required by various applications. The extruded or rolled material is then thermally rearranged by heating to about 250 C for about 4 days to form the finished compound as described in Yuan.
  • antibacterial salts such as silver in its various salt forms are used to dope the resulting compounds.
  • a process and composition of material that allows the efficient and cost effective production of a hemostatic paste for use in multiple applications is contemplated.
  • a starch or starch like material is incorporated into an ointment or cream base known in the art with an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • Various salt forms of calcium are incorporated to accelerate the clotting process.
  • an emollient known in the art including but not limited to Glycerol is incorporated into the hemostatic paste according to the disclosure.
  • a hemostatic paste is formed of the following components: Amylpectin phosphate, 2-hydroxyproply ether 0.1% to 90% w/v Silver citrate 0.01 % to 90% w/v
  • a process and composition of material that allows the efficient and cost effective production of a hemostatic aerosol for use in multiple applications is contemplated.
  • a starch, starch like material or hydrophilic polymer is finely ground and incorporated in its dry form with an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • Various salt forms of calcium are incorporated to accelerate the clotting process.
  • Dry flow compositions known in the art are incorporate allowing the above powder to be dispensed in an aerosol form.
  • the hemostatic aerosol is formed of the following components: Amylpectin phosphate, 2-hydroxyproply ether 0.1 % to 90% w/v Silver citrate 0.01% to 90% w/v
  • a process and composition of material that allows the efficient and cost effective production of a hemostatic containment package to hold hemostatic material for use in multiple applications is contemplated.
  • Various salt forms of calcium are incorporated to accelerate the clotting process.
  • the hemostatic containment package is formed in a manner allowing hemostatic agents to be placed within.
  • the hemostatic containment package is formed of a natural fiber fabric that is hydrophilic and adsorbent. If the selected material is hydrophobic in nature treatment with a surfactant will allow the fabric to become somewhat adsorbent.
  • a cloth type containment package is treated with a solution of a silver salt and calcium salt along with a surfactant. The treated containment package is allowed to dry and a starch like hemostatic product is added to the treated containment package. It is contemplated within the scope of the disclosure that other hemostatic agents can be used or optionally mixed with the starch or starch like product.
  • the components of the containment package contain the following components: Amylpectin phosphate, 2-hydroxyproply ether 0.1% to 90% w/v
  • Example VI In a further illustrative embodiment according to the disclosure a process and composition of material that allows the efficient and cost effective production of a hemostatic bandage for use in multiple applications is contemplated.
  • a starch or starch like material or hydrophilic polymer is finely ground and incorporated with an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • Various salt forms of calcium are incorporated to accelerate the clotting process.
  • Binding compositions known in the art are also incorporated allowing the above mixture to be adhered to a natural or polymeric fabric.
  • the hemostatic bandage is formed of a natural fiber with the following components of a mixture adhered to it: Amylpectin phosphate, 2-hydroxyproply ether 0.1% to 90% w/v
  • Example VII In a further illustrative embodiment according to the disclosure a process and composition of material that allows the efficient and cost effective production of a physiologically degradable hemostatic bandage for use in multiple applications is contemplated.
  • a starch or starch like material is finely ground and incorporated with an antimicrobial such as soluble silver salts in a concentration of about 100 ppm to about 10000 ppm.
  • Various salt forms of calcium are further incorporated to accelerate the clotting process.
  • Binding compositions known in the art are incorporated allowing the above mixture to be adhered or embedded into a physiologically degradable polymeric sheet.
  • physiologically degradable polymeric sheet is formed into a thin sheet and wrapped around hemostatic material.
  • physiologically degradable polymeric sheet is embedded with a hemostatic material and formed into thin strips that can be placed within a wound having various contours.
  • physiologically degradable polymeric sheet has the following mixture of components adhered to it:
  • the illustrative embodiments within the disclosure disclose the use of molecular sieve in either paper-like or rubber-like forms for medical uses as hemostatic agents, it will also be appreciated by those skilled in the art that the molecular sieves according to the disclosure can be used as reaction catalysts. Likewise, it will be appreciated by those skilled in the art that the molecular sieve according to the disclosure can be used in petroleum refining. Similarly, those skilled in the art will appreciate that the molecular sieve according to the invention may be used in drug delivery systems. It will further be appreciated by those skilled in the art that the molecular sieve according to the disclosure can be used in applications such as air filtration, liquid filtration and as liquid purifiers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne une composition et un procédé permettant d'appliquer et d'enlever aisément un agent hémostatique sous forme granulaire. Dans un premier mode de réalisation à titre d'illustration, l'agent hémostatique est un oxyde de manganèse synthétique comportant une structure cristalline choisie. Quand il est attaché à des matières ou enfermé dans des matières, l'oxyde de manganèse adsorbe efficacement l'eau d'un écoulement de liquides organiques et il concentre la matière cellulaire pour engager le processus de coagulation. L'invention concerne en outre un procédé de fabrication de tamis moléculaires dans des formes semblables à du papier ou à du caoutchouc. Ces formes permettent une utilisation plus efficace du tamis moléculaire dans diverses applications industrielles.
PCT/US2006/035417 2005-09-13 2006-09-13 Procédé de fabrication d'agents hémostatiques et leurs utilisations Ceased WO2007033135A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71678405P 2005-09-13 2005-09-13
US60/716,784 2005-09-13
US72403005P 2005-10-06 2005-10-06
US60/724,030 2005-10-06

Publications (2)

Publication Number Publication Date
WO2007033135A2 true WO2007033135A2 (fr) 2007-03-22
WO2007033135A3 WO2007033135A3 (fr) 2009-04-23

Family

ID=37865504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035417 Ceased WO2007033135A2 (fr) 2005-09-13 2006-09-13 Procédé de fabrication d'agents hémostatiques et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2007033135A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106377792A (zh) * 2016-09-29 2017-02-08 江苏华能药业有限公司 复合微孔交联淀粉止血粉
CN106606799A (zh) * 2016-08-18 2017-05-03 中国人民解放军第二军医大学 一种多孔淀粉复合材料及其制备方法和应用
WO2019242391A1 (fr) * 2018-06-18 2019-12-26 浙江大学 Complexe hémostatique et son procédé de préparation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340562A (en) * 1993-04-02 1994-08-23 Texaco Inc. Hydrothermal synthesis of octahedral molecular sieve
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
DE10008499A1 (de) * 1999-03-08 2000-09-28 Idemitsu Petrochemical Co Verfahren zur Abtrennung von festen Nicht-Lithiumhydroxid-Verbindungen
EP1663090A4 (fr) * 2003-09-12 2010-07-21 Z Medica Corp Agent hemostatique de zeolite de calcium

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106606799A (zh) * 2016-08-18 2017-05-03 中国人民解放军第二军医大学 一种多孔淀粉复合材料及其制备方法和应用
CN106377792A (zh) * 2016-09-29 2017-02-08 江苏华能药业有限公司 复合微孔交联淀粉止血粉
WO2019242391A1 (fr) * 2018-06-18 2019-12-26 浙江大学 Complexe hémostatique et son procédé de préparation
US11154512B2 (en) 2018-06-18 2021-10-26 Hangzhou Zeo-Innov Life Technology Co., Ltd Hemostatic compound and preparation method thereof

Also Published As

Publication number Publication date
WO2007033135A3 (fr) 2009-04-23

Similar Documents

Publication Publication Date Title
US12076448B2 (en) Hemostatic devices
AU2017201139B2 (en) Hemostatic Devices
EP2077811B1 (fr) Agents hémostatiques à base d'argile, et dispositifs pour leur administration
US8383148B2 (en) Clay-based hemostatic agents and devices for the delivery thereof
US20070134293A1 (en) Devices and methods for the delivery of blood clotting materials to bleeding wounds
WO2007033135A2 (fr) Procédé de fabrication d'agents hémostatiques et leurs utilisations
US20120015022A1 (en) Biodegradable wound care products with biocompatible artificial skin treatment
US20240033398A1 (en) Hemostatic devices
US20130018334A1 (en) Biodegradable wound care products with biocompatible artificial skin treatment and healing accelerator
HK1170147A (en) Clay-based hemostatic agents and devices for the delivery thereof
HK1135892B (en) Clay-based hemostatic agents and devices for the delivery thereof
HK1230110A1 (en) Clay-based hemostatic agents and devices for the delivery thereof
HK1136227B (en) Clay-based hemostatic agents and devices for the delivery thereof
HK1206650B (en) Hemostatic devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112 (1) EPC, EPO FORM 1205A DATED 28.07.08

122 Ep: pct application non-entry in european phase

Ref document number: 06803387

Country of ref document: EP

Kind code of ref document: A2

Free format text: NOTHING LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC,EPO FORM 1205A DATED 20/05/08

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTHING LOSS OF RIGHTS PURSUANT TO RULE 112(1)EPC,EPO FORM 1205A DATED 20/05/08